Ridgetech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ridgetech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Consumer Retailing earnings growth	9.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Oct 30

China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) Stocks Shoot Up 32% But Its P/S Still Looks Reasonable

China Jo-Jo Drugstores, Inc. ( NASDAQ:CJJD ) shareholders are no doubt pleased to see that the share price has bounced...

Seeking Alpha • Jul 28

China Jo - Jo Drugstores GAAP EPS of -$0.92, revenue of $164.39M

China Jo - Jo Drugstores press release (NASDAQ:CJJD): FY GAAP EPS of -$0.92. Revenue of $164.39M (+23.5% Y/Y). Revenue increased by 23.5% to $164.39 million for the fiscal year ended March 31, 2022 from $133.13 million for the same period of last year. Gross profit increased by 24.9% to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year. Gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022 from 22.0% for the same period of last year. Revenue for the fiscal year ended March 31, 2022 increased by $31.25 million, or 23.5%, to $164.39 million from $133.13 million for the same period of last year. The increase in revenue was primarily due to the growth in retail drugstores, online pharmacy and wholesale business.

Analysis Article • Feb 09

China Jo-Jo Drugstores' (NASDAQ:CJJD) Stock Price Has Reduced 24% In The Past Five Years

Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ridgetech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:RDGT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	132	-1	-1	-1	N/A
12/31/2025	118	1	7	8	N/A
9/30/2025	120	-2	16	17	N/A
6/30/2025	120	-2	8	9	N/A
3/31/2025	120	-1	1	1	N/A
9/30/2024	147	-6	-15	-14	N/A
6/30/2024	151	-5	-10	-8	N/A
3/31/2024	124	-1	-4	-3	N/A
12/31/2023	155	-13	-4	-3	N/A
9/30/2023	155	-21	-4	-4	N/A
6/30/2023	152	-21	-4	-3	N/A
3/31/2023	120	-16	-4	-3	N/A
12/31/2022	154	-12	-4	-4	N/A
9/30/2022	159	-4	-5	-5	N/A
6/30/2022	162	-3	-5	-5	N/A
3/31/2022	164	-3	-6	-5	N/A
12/31/2021	157	-2	9	10	N/A
9/30/2021	150	-7	0	1	N/A
6/30/2021	141	-8	5	6	N/A
3/31/2021	133	-8	-1	0	N/A
12/31/2020	128	-11	-9	-8	N/A
9/30/2020	126	-4	-9	-8	N/A
6/30/2020	123	-4	-6	-4	N/A
3/31/2020	117	-6	-9	-7	N/A
12/31/2019	113	0	N/A	-7	N/A
9/30/2019	111	-2	N/A	-2	N/A
6/30/2019	110	-2	N/A	-11	N/A
3/31/2019	108	-1	N/A	-6	N/A
12/31/2018	105	-17	N/A	-3	N/A
9/30/2018	101	-17	N/A	-4	N/A
6/30/2018	97	-16	N/A	-1	N/A
3/31/2018	96	-17	N/A	-2	N/A
12/31/2017	92	-9	N/A	-6	N/A
9/30/2017	86	-8	N/A	1	N/A
6/30/2017	82	-7	N/A	1	N/A
3/31/2017	81	-6	N/A	2	N/A
12/31/2016	82	0	N/A	2	N/A
9/30/2016	86	0	N/A	2	N/A
6/30/2016	89	0	N/A	1	N/A
3/31/2016	89	0	N/A	3	N/A
12/31/2015	89	1	N/A	1	N/A
9/30/2015	86	2	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RDGT's forecast earnings growth is above the savings rate (3.7%).

Earnings vs Market: Insufficient data to determine if RDGT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if RDGT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RDGT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if RDGT's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RDGT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/17 22:38
End of Day Share Price	2026/09/17 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ridgetech, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Ridgetech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Ridgetech, Inc., Annual General Meeting, Aug 25, 2026

Full year 2026 earnings released: US$17.21 loss per share (vs US$39.50 loss in FY 2025)

New major risk - Market cap size

First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)

New minor risk - Financial data availability

Now 27% undervalued

Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Now 27% undervalued

Ridgetech, Inc., Annual General Meeting, Dec 12, 2025

Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024)

New major risk - Share price stability

China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025

New major risk - Market cap size

First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024)

China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) Stocks Shoot Up 32% But Its P/S Still Looks Reasonable

New major risk - Share price stability

New major risk - Market cap size

Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023)

China Jo-Jo Drugstores, Inc. Announces Resignation of Pingfan Wu as Member of the Board of Directors

China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million.

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023

New major risk - Market cap size

China Jo-Jo Drugstores Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022)

Insufficient new directors

Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021)

China Jo - Jo Drugstores GAAP EPS of -$0.92, revenue of $164.39M

China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price Requirement

First half 2022 earnings released

Insufficient new directors

Full year 2021 earnings released: US$0.20 loss per share (vs US$0.18 loss in FY 2020)

New 90-day low: US$0.98

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.016 profit in 3Q 2020)

China Jo-Jo Drugstores' (NASDAQ:CJJD) Stock Price Has Reduced 24% In The Past Five Years

New 90-day high: US$1.24

New 90-day high: US$1.15

China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement

Second quarter 2021 earnings released: US$0.039 loss per share

New 90-day low: US$0.90

New 90-day low: US$0.91

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources